Revolutionising cancer diagnostics
A step change in the detection, diagnosis and monitoring of disease.
Biofidelity’s unique technology enables fast, simple and ultra-sensitive detection of genetic panels from both tissue and liquid biopsies using existing laboratory instrumentation.
ASPYRE-Lung
Comprehensive coverage of NCCN guideline recommended markers for NSCLC
- 111 markers across 11 genes
- 0.1% allele-fraction sensitivity in a simple workflow
- Simultaneous DNA & RNA analysis on one instrument
Latest News
15 July 2021
Biofidelity wins Start Up of the Year at the Cambridge Independent Science & Technology Awards
16 April 2021
16 April 2021
07 April 2021
Biofidelity announces first peer reviewed publication of breakthrough ASPYRE technology
23 March 2021
23 March 2021